NORD and University of Maryland partner for rare-disease research training
July 16, 2015
7:00 pm
The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.
Five things for pharma marketers to know: Tuesday, July 7
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
Five things for pharma marketers to know: Thursday, June 11
Amgen’s PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire’s hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups
Everyday Health looks to compete for pharma TV budgets
Amgen raises price of Enbrel by 10%; pharma companies appear to raise diabetes drug prices in tandem; Alexion agrees to buy rare-disease drugmaker for $8.4 billion
Five things for pharma marketers to know: Friday, May 1
Nexium tops the list of Medicare’s spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
Five things for pharma marketers to know: Friday, April 10
AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce
Rituxan may have rare-disease use
April 6, 2015
7:04 pm
The cancer and immunology drug may help patients with a condition that affects two people in every one million.